Prevention of Huntington's Disease-Like Behavioral Deficits in R6/1 Mouse by Tolfenamic Acid Is Associated with Decreases in Mutant Huntingtin and Oxidative Stress

Tolfenamic acid is a nonsteroidal anti-inflammatory drug with neuroprotective properties, and it alleviates learning and memory deficits in the APP transgenic mouse model of Alzheimer's disease. However, whether tolfenamic acid can prevent motor and memory dysfunction in transgenic animal models of Huntington's disease (HD) remains unclear. To this end, tolfenamic acid was orally administered to transgenic R6/1 mice from 10 to 20 weeks of age, followed by several behavioral tests to evaluate motor and memory function. Tolfenamic acid improved motor coordination in R6/1 mice as tested by rotarod, grip strength, and locomotor behavior tests and attenuated memory dysfunction as analyzed using the novel object recognition test and passive avoidance test. Tolfenamic acid decreased the expression of mutant huntingtin in the striatum of 20-week-old R6/1 mice by inhibiting specificity protein 1 expression and enhancing autophagic function. Furthermore, tolfenamic acid exhibited antioxidant effects in both R6/1 mice and PC12 cell models. Collectively, these results suggest that tolfenamic acid has a good therapeutic effect on R6/1 mice, and may be a potentially useful agent in the treatment of HD.

[1]  Dechun Li,et al.  SP1 reduces autophagic flux through activating p62 in gastric cancer cells. , 2018, Molecular medicine reports.

[2]  P. Liu,et al.  Xanthoceraside attenuates amyloid &bgr; peptide1‐42‐induced memory impairments by reducing neuroinflammatory responses in mice , 2018, European journal of pharmacology.

[3]  P. Liu,et al.  Time-course investigation of blood–brain barrier permeability and tight junction protein changes in a rat model of permanent focal ischemia , 2018, The Journal of Physiological Sciences.

[4]  Hui Sun,et al.  Nrf2-mediated neuroprotection by MANF against 6-OHDA-induced cell damage via PI3K/AKT/GSK3β pathway , 2017, Experimental Gerontology.

[5]  S. Pyo,et al.  Pneumolysin-induced autophagy contributes to inhibition of osteoblast differentiation through downregulation of Sp1 in human osteosarcoma cells. , 2017, Biochimica et biophysica acta. General subjects.

[6]  H. Li,et al.  Thymoquinone protects against cobalt chloride-induced neurotoxicity via Nrf2/GCL-regulated glutathione homeostasis. , 2017, Journal of biological regulators and homeostatic agents.

[7]  K. Ghaedi,et al.  Huntington’s Disease and Mitochondria , 2017, Neurotoxicity Research.

[8]  M. Essa,et al.  Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington's Disease , 2017, Oxidative medicine and cellular longevity.

[9]  Gilles J Guillemin,et al.  The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review , 2016, Oxidative medicine and cellular longevity.

[10]  C. Isidoro,et al.  Dopamine exacerbates mutant Huntingtin toxicity via oxidative-mediated inhibition of autophagy in SH-SY5Y neuroblastoma cells: Beneficial effects of anti-oxidant therapeutics , 2016, Neurochemistry International.

[11]  Shi-feng Chu,et al.  20C, a bibenzyl compound isolated from Gastrodia elata, protects PC12 cells against rotenone-induced apoptosis via activation of the Nrf2/ARE/HO-1 signaling pathway , 2016, Acta Pharmacologica Sinica.

[12]  A. Hannan,et al.  Therapeutic Effects of Anthocyanins and Environmental Enrichment in R6/1 Huntington's Disease Mice. , 2016, Journal of Huntington's disease.

[13]  A. Rego,et al.  Protective effects of 3-alkyl luteolin derivatives are mediated by Nrf2 transcriptional activity and decreased oxidative stress in Huntington's disease mouse striatal cells , 2015, Neurochemistry International.

[14]  Hong Zhu,et al.  Mechanisms of CDDO-imidazolide-mediated cytoprotection against acrolein-induced neurocytotoxicity in SH-SY5Y cells and primary human astrocytes. , 2015, Toxicology letters.

[15]  S. Ganapasam,et al.  Neuroprotective efficacy of naringin on 3-nitropropionic acid-induced mitochondrial dysfunction through the modulation of Nrf2 signaling pathway in PC12 cells , 2015, Molecular and Cellular Biochemistry.

[16]  R. Basha,et al.  Tolfenamic acid reduces tau and CDK5 levels: implications for dementia and tauopathies , 2015, Journal of Neurochemistry.

[17]  A. Hannan,et al.  N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease , 2015, Translational Psychiatry.

[18]  Peng Liu,et al.  Sigma 1 receptor activation regulates brain-derived neurotrophic factor through NR2A-CaMKIV-TORC1 pathway to rescue the impairment of learning and memory induced by brain ischaemia/reperfusion , 2015, Psychopharmacology.

[19]  Qian Xu,et al.  Xanthoceraside rescues learning and memory deficits through attenuating beta-amyloid deposition and tau hyperphosphorylation in APP mice , 2014, Neuroscience Letters.

[20]  Lingling Zhai,et al.  Leptin Level and Oxidative Stress Contribute to Obesity-Induced Low Testosterone in Murine Testicular Tissue , 2014, Oxidative medicine and cellular longevity.

[21]  N. Zawia,et al.  Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer's disease related biomarkers , 2014, Neuropharmacology.

[22]  Mal-Soon Shin,et al.  Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson's disease. , 2014, International journal of molecular medicine.

[23]  F. Gage,et al.  Mutant Huntingtin Promotes Autonomous Microglia Activation via Myeloid Lineage-determining Factors Fold Difference from the Mean , 2022 .

[24]  A. Giralt,et al.  Prostaglandin E2 EP1 Receptor Antagonist Improves Motor Deficits and Rescues Memory Decline in R6/1 Mouse Model of Huntington's Disease , 2014, Molecular Neurobiology.

[25]  Anil Kumar,et al.  Minocycline modulates neuroprotective effect of hesperidin against quinolinic acid induced Huntington's disease like symptoms in rats: behavioral, biochemical, cellular and histological evidences. , 2013, European journal of pharmacology.

[26]  N. Zawia,et al.  Short-term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease mice , 2013, Neurobiology of Aging.

[27]  D. Eslin,et al.  Cellular and Organismal Toxicity of the Anti-Cancer Small Molecule, Tolfenamic Acid: a Pre-Clinical Evaluation , 2013, Cellular Physiology and Biochemistry.

[28]  Wei Zhou,et al.  Sp1 Regulates Human Huntingtin Gene Expression , 2012, Journal of Molecular Neuroscience.

[29]  Anil Kumar,et al.  Expression of Concern: Role of LOX/COX pathways in 3‐nitropropionic acid‐induced Huntington's Disease‐like symptoms in rats: protective effect of licofelone , 2011, British journal of pharmacology.

[30]  R. Basha,et al.  Tolfenamic acid interrupts the de novo synthesis of the β-amyloid precursor protein and lowers amyloid beta via a transcriptional pathway. , 2011, Current Alzheimer research.

[31]  Anil Kumar,et al.  Licofelone attenuates quinolinic acid induced Huntington like symptoms: Possible behavioral, biochemical and cellular alterations , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[32]  K. Merienne,et al.  Transcriptional Activation of REST by Sp1 in Huntington's Disease Models , 2010, PloS one.

[33]  H. Kalonia,et al.  Protective effect of montelukast against quinolinic acid/malonic acid induced neurotoxicity: possible behavioral, biochemical, mitochondrial and tumor necrosis factor-α level alterations in rats , 2010, Neuroscience.

[34]  Chuan-en Wang,et al.  Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms , 2009, Proceedings of the National Academy of Sciences.

[35]  S. Barger,et al.  Unique aspects of transcriptional regulation in neurons – nuances in NFκB and Sp1-related factors , 2009, Journal of Neuroinflammation.

[36]  C. Blakemore,et al.  Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease , 2008, BMC Neuroscience.

[37]  Shihua Li,et al.  Context-dependent Dysregulation of Transcription by Mutant Huntingtin* , 2006, Journal of Biological Chemistry.

[38]  M. Abdelrahim,et al.  Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. , 2006, Journal of the National Cancer Institute.

[39]  S. Hersch,et al.  Sp1 Is Up-regulated in Cellular and Transgenic Models of Huntington Disease, and Its Reduction Is Neuroprotective* , 2006, Journal of Biological Chemistry.

[40]  M. MacDonald,et al.  Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease , 2006, Neurobiology of Disease.

[41]  R. Neve,et al.  Sp1 and Sp3 Are Oxidative Stress-Inducible, Antideath Transcription Factors in Cortical Neurons , 2003, The Journal of Neuroscience.

[42]  Dimitri Krainc,et al.  Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease , 2002, Science.